SCHEMBL5582267

SCHEMBL5582267

CNc1ncc2c(-c3cc(Cl)ccc3Cl)cc(-c3ccc(C(=O)O)cc3)c(OC)c2n1

nearest known ligand 0.46

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CSNK2A1 P68400 9/20 0.46
CSNK2A2 P19784 4/20 0.45
CSNK2B P67870 4/20 0.45
LRRK2 Q5S007 2/20 0.41
SRD5A2 P31213 1/20 0.40
PHLPP2 Q6ZVD8 1/20 0.39
RORC P51449 2/20 0.37
MAP4K4 O95819 1/20 0.37
AURKA O14965 1/20 0.37
GABRA1 P14867 1/20 0.37
AURKB Q96GD4 1/20 0.37
SIK1 P57059 1/20 0.36
SIK2 Q9H0K1 1/20 0.36
SIK3 Q9Y2K2 1/20 0.36
PTK2 Q05397 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5582010 0.91 CSNK2A2 (0.47) CSNK2A1CSNK2A2CSNK2BLRRK2SRD5A2
SCHEMBL5581859 0.90 MAP4K4 (0.47) CSNK2A1CSNK2A2CSNK2BLRRK2RORC
SCHEMBL5582325 0.89 KMO (0.43) CSNK2A1CSNK2A2CSNK2BLRRK2MAP4K4
SCHEMBL5582255 0.88 CSNK2A1 (0.43) CSNK2A1CSNK2A2CSNK2BLRRK2SRD5A2
SCHEMBL5582212 0.87 CSNK2A1 (0.49) CSNK2A1CSNK2A2CSNK2BLRRK2MAP4K4
SCHEMBL5581713 0.87 CSNK2A1 (0.42) CSNK2A1CSNK2A2CSNK2BLRRK2MAP4K4
SCHEMBL5581693 0.86 CSNK2A1 (0.45) CSNK2A1CSNK2A2CSNK2BLRRK2RORC
SCHEMBL5582013 0.86 CSNK2A1 (0.51) CSNK2A1CSNK2A2CSNK2BLRRK2
SCHEMBL5582330 0.85 CSNK2A1 (0.48) CSNK2A1CSNK2A2CSNK2BMAP4K4PTK2
SCHEMBL5582036 0.84 PTPN11 (0.43) CSNK2A1CSNK2A2CSNK2BLRRK2MAP4K4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070225308-A1 2-Amino Quinazoline Derivative KYOWA HAKKO KOGYO CO.,LTD. (JP) 2007-09-27 US disclosed
EP-1726584-A1 2-AMINOQUINAZOLINE DERIVATIVE KYOWA HAKKO KOGYO CO., LTD. (JP) 2006-11-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070225308-A1 2-Amino Quinazoline Derivative AGTR2, ABL1, AGTR1 CSNK2A1 602/4885CSNK2A2 467/4885CSNK2B 662/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.